Diligence memo · auto-generated · as of July 2, 2026
PharmAbbie, Inc.
PharmAbbie, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
PharmAbbie, Inc. operates in Pharmaceuticals, based in GROTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
PharmAbbie, Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2021-08-12.
Most recent recorded round closed around 2021-08-12.
Valuation (modeled)modeled
Provath models PharmAbbie, Inc. at approximately $282M (range $17M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.85× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.9 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 61% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.